Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United KingdomIPO:
28 April 2017Website:
http://www.veronapharma.comNext earnings report:
28 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | 41 min agoDividend
Analysts recommendations
Institutional Ownership
VRNA Latest News
LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in December 2024:
Verona Pharma has seen its share price skyrocket in anticipation of the commercial launch of its COPD treatment.
LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 6:30 a.m. ET / 11:30 a.m. GMT.
Verona Pharma plc (NASDAQ:VRNA ) Q3 2024 Earnings Conference Call November 4, 2024 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Officer Christopher Martin - Chief Commercial Officer Tara Rheault - Chief Development Officer Conference Call Participants Andrew Tsai - Jefferies Yasmeen Rahimi - Piper Sandler. Raghuram Selvaraju - HC Wainwright Tom Shrader - BTIG Edward Thomason - VLK Joon Lee - Truist Boobalan Pachaiyappan - Roth Capital Partners Operator Good morning, everyone, and welcome to Verona Pharma's Third Quarter 2024 Financial Results and Operating Highlights Conference Call.
Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3
LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.
Verona Pharma announces four oral presentations and two posters on analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) at CHEST 2024.
Verona Pharma's Ohtuvayre (ensifentrine) was approved for COPD in June 2024, introducing a novel dual mechanism of action. Ohtuvayre is priced at $2,950 per month, significantly above ICER's cost-effectiveness benchmark of $7,500–$12,700 annually. The drug targets patients who experience exacerbations despite traditional triple therapy (LABA, LAMA, ICS), addressing an unmet need in COPD treatment.
Verona Pharma presents one oral presentation and 3 posters on additional analyses from its successful Phase 3 ENHANCE studies with Ohtuvayre at ERS 2024.
Verona Pharma plc (NASDAQ:VRNA ) Q2 2024 Earnings Conference Call August 8, 2024 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Officer Christopher Martin - Chief Commercial Officer Tara Rheault - Chief Development Officer Conference Call Participants Andrew Tsai - Jefferies Group LLC Thomas Shrader - BTIG, LLC Raghuram Selvaraju - H.C. Wainwright & Co. Edward Thomason - Van Lanschot Kempen Operator Welcome to Verona Pharma's Second Quarter 2024 Financial Results and Operating Highlights Conference Call.
- 1(current)
- 2
What type of business is Verona Pharma?
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
What sector is Verona Pharma in?
Verona Pharma is in the Healthcare sector
What industry is Verona Pharma in?
Verona Pharma is in the Biotechnology industry
What country is Verona Pharma from?
Verona Pharma is headquartered in United Kingdom
When did Verona Pharma go public?
Verona Pharma initial public offering (IPO) was on 28 April 2017
What is Verona Pharma website?
https://www.veronapharma.com
Is Verona Pharma in the S&P 500?
No, Verona Pharma is not included in the S&P 500 index
Is Verona Pharma in the NASDAQ 100?
No, Verona Pharma is not included in the NASDAQ 100 index
Is Verona Pharma in the Dow Jones?
No, Verona Pharma is not included in the Dow Jones index
When was Verona Pharma the previous earnings report?
No data
When does Verona Pharma earnings report?
The next expected earnings date for Verona Pharma is 28 February 2025